CBAY News and Press, CymaBay Therapeutics Inc. From 06/21/21

New analyses adds to the growing body of evidence for seladelpar’s potential as a treatment for patients with PBC NEWARK, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on develop...

NEWARK, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that multiple seladelpar presentations will be d...

Image source: The Motley Fool. CymaBay Therapeutics Inc. (NASDAQ: CBAY) Q1 2021 Earnings Call May 13, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: CymaBay Therapeutics Inc. (CBAY) Q1 2021 Earnings Call Transcript...

Cymabay Therapeutics, Inc. (CBAY) Q1 2021 Earnings Conference Call May 13, 2021, 16:30 ET Company Participants Daniel Menold - VP, Finance Sujal Shah - President, CEO & Director Charles McWherter - SVP & Chief Scientific Officer Conference Call Participants Yasmeen Rahimi - Piper Sand...

Highly experienced executives, Dr. Dennis Kim as Chief Medical Officer and Lewis Stuart as Chief Commercial Officer, strengthen the management team Biopharma leaders, Thomas Wiggans and Janet Dorling, appointed to the Board of Directors Actively recruiting patients in tw...

NEWARK, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that medical and clinical leader Dennis D. Kim, M...

NEWARK, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the grant of an inducement award to Lewis Stuart ...

Proven Leader in Building Commercial Organizations to Prepare Markets and Deliver Successful Product Launches Planning for Seladelpar Launch as it Completes Development and Regulatory Submissions NEWARK, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASD...

NEWARK, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audi...

Gainers: [[XM]] +7.9%. [[CHDN]] +6.0%. [[IRDM]] +4.8%. [[UFPI]] +4.8%. [[SYBX]] +4.4%.Losers: [[EOLS]] -13.7%. [[AZN]] -7.9%. [[CBAY]] -6.6%. [[SNBR]] -6.0%. [[CENX]] -5.7%. For further details see: XM, IRDM, EOLS and AZN among after-hours movers